Johnson & Johnson Earnings Release: Q4 2021 – sales growth of 11.6%
Johnson & Johnson Earnings Release: Q4 2021
Johnson & Johnson (NYSE: JNJ) today announced results for the fourth quarter and full-year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well-positioned for success in 2022 and beyond.”
2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%, and adjusted operational sales growth of 12.3%
• 2021 Full-Year Sales of $93.8 Billion reflecting growth of 13.6%, operational sales growth of 12.2%, and adjusted operational sales growth of 12.8%
• 2021 Fourth-Quarter EPS of $1.77 increased 172.3%; adjusted EPS of $2.13 increased 14.5%*
• 2021 Full-Year EPS of $7.81 increased 41.7%; adjusted EPS of $9.80 increased 22.0%*
• Company guides 2022 adjusted operational sales growth of 7.7%* and adjusted operational EPS growth of 9.2%*
